Trial
NCT02031445
Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Celsus Therapeutics PLC
Collaborators
—
Condition
Atopic Dermatitis
Intervention
MRX-6
Why stopped
Interim analysis showed lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-06